P-170在急性白血病中的表达及其临床意义

Clinical significance of P-170 expression in acute leukemia

关键词:  急性白血病  P-170  流式细胞术

Key words:  acute leukemia  P-170  flow cytometry

摘要:

［目的］探讨P-170在急性白血病中的表达及其与该疾病预后的关系。［方法］ 选取191例急性白血病患者，其中初发患者127例［急性非淋巴细胞白血病（AML）组94例，急性淋巴细胞白血病（ALL）组33例］，复发患者64例（AML组45例，ALL组19例）。流式细胞仪测定上述病人骨髓细胞表面P-170的表达，并计算各组病人P-170的表达率。此外，对所有初发患者进行正规化疗，比较P-170阴性患者与阳性患者治疗的完全缓解率。［结果］ 初发AML组P-170表达率为（18.34±12.19）%，P-170阳性患者率为12.7%（12/94）；初发ALL组P-170表达率为（16.25±11.47）%，P-170阳性患者率为15.1%（5/33）。与初发组病人相比较，复发AML和ALL组P-170表达率和P-170阳性患者率均明显高于相应的初发组［复发AML组（35.29±16.82）%，68.8%（31/45），P<0.01；复发ALL组（38.24±12.17）%，68.4%（13/19），P<0.01］。无论初发AML或ALL，正规化疗后，P-170阴性患者完全缓解率［AML：86%（74/86）；ALL：85%（24/28）］明显高于P-170阳性患者［AML：16%（2/12）；ALL：0% （0/5）］。［结论］ P-170可作为临床判断急性白血病疗效和预后的指标。

Abstract:

［Objective］ To investigate the expression of P-170 in acute leukemia patients and its relationship with the prognosis of this disease. ［Methods］ One hundred ninety-one acute leukemia patients were divided into primordial group (n=127, 94 AML patients and 33 ALL patients) and recurrent group (n=64, 45 AML patients and 19 ALL patients). The expression of P-170 in bone marrow cells was detected by flow cytometry, and was compared between primordial and recurrent groups. In addition, all the primordial patients received a formal chemotherapy. Complete remission (CR) was compared between P-170 positive and negative patients. ［Results］ In the primordial group, the expression of P-170 was 18.34±12.19% in AML patients and 16.25±11.47% in ALL patients, while the percentage of P-170 positive patient was 12.7% (12/94) in AML patients and 15.1% (5 /33) in ALL patients respectively. Compared to primordial group, the expression of P170 significantly increased in recurrent group [AML: (35.29±16.82) % vs 68.8%(31/45), P<0.01; ALL:(38.24±12.17)% vs 68.4%(13/19), P<0.01]. After chemotherapy, the CR percentage of P-170 negative patients [AML:86% (74/86); ALL:85% (24/28)] was significantly higher than that of P-170 positive patients [AML:16% (2/12); ALL:0% (0/5)] (P<0.01). ［Conclusion］ P-170 might be a promising marker in evaluating the therapeutic efficacy and prognosis of acute leukemia.